Cases & Deals

Inotrem raises €44 million in Series B round

Clients Inotrem SA

Jones Day advised Inotrem SA, a French biotech company specialized in immunotherapy for acute and chronic inflammatory syndromes, in connection with its €44 million Series B round of financing led by Morningside Ventures.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.